| 中文名称 | 六羟黄酮/栎草亭 |
| 英文名称 | 3,3',4',5,6,7-HEXAHYDROXYFLAVONE |
| CAS号 | 90-18-6 |
| 分子式 | C15H10O8 |
| 分子量 | 318.24 |
| EINECS号 | 201-973-6 |
| 熔点 | >300°C |
| 沸点 | 732.4±60.0 °C(Predicted) |
| 密度 | 1.912±0.06 g/cm3(Predicted) |
| LogP | 2.230 (est) |
| 溶解度 | DMSO:125 mg/mL(392.79 mM;需要超声波) |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 6.12±0.40(Predicted) |
| 颜色 | 浅黄至黄色 |
|
PIM1 0.34 μM (IC 50 ) |
PIM2 3.45 μM (IC 50 ) |
RSK2 2.82 μM (IC 50 ) |
PKA 21.2 μM (IC 50 ) |
Quercetagetin also inhibits PIM2, PKA, and RSK2 with IC
50
s of 3.45, 21.2, and 2.82 µM, respectively.
Quercetagetin (0.1, 1, 10, and 100 μM, 72 hours) inhibits growth of RWPE2 prostate cancer cells with average ED
50
is 3.8 μM.
Cell Viability Assay
| Cell Line: | RWPE2 prostate cancer cells |
| Concentration: | 0.1, 1, 10, and 100 μM |
| Incubation Time: | 72 hours |
| Result: | Inhibited growth of RWPE2 prostate cancer cells with average ED 50 is 3.8 μM. |
Quercetagetin significantly inhibits UVB-induced skin cancer development. Topical application of 4 or 20 nmol of Quercetagetin to mouse skin reduces tumor incidence by 32.0% and 46.7%, respectively.
| Animal Model: | SKH-1 hairless mice model |
| Dosage: | 4 or 20 nmol |
| Administration: | Topical application; 28 weeks |
| Result: | Inhibited UVB-induced skin tumorigenesis in SKH-1 hairless mice models. Delayed the development of tumors and reduced tumor volumes in an SKH-1 hairless mice model. |